| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10549-017-4162-3 |
| P698 | PubMed publication ID | 28243896 |
| P50 | author | Megan C Roberts | Q61121082 |
| P2093 | author name string | Steven Shak | |
| Dave P Miller | |||
| Valentina I Petkov | |||
| P2860 | cites work | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial | Q24597456 |
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data | Q30497053 | ||
| Comparison of SEER Treatment Data With Medicare Claims | Q30779910 | ||
| Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study | Q33915023 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay | Q34114888 | ||
| Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. | Q34190743 | ||
| The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists | Q35599773 | ||
| The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007) | Q36364504 | ||
| Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. | Q36914381 | ||
| Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer | Q37095310 | ||
| Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. | Q40600945 | ||
| Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study | Q43138098 | ||
| The influence of a gene expression profile on breast cancer decisions | Q46127572 | ||
| The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. | Q51131525 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | database | Q8513 |
| breast cancer | Q128581 | ||
| lymph node | Q170758 | ||
| P304 | page(s) | 303-310 | |
| P577 | publication date | 2017-02-27 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database | |
| P478 | volume | 163 |
| Q90069322 | 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes |
| Q89572799 | Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer |
| Q92309779 | Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? |
| Q57107755 | Clinical relevance of the 21-gene Recurrence Score assay in treatment decisions for patients with node-positive breast cancer in the genomic era |
| Q58615716 | Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? |
| Q64228159 | Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis |
| Q57116157 | Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer |
| Q99550458 | Landmark trials in the medical oncology management of early stage breast cancer |
| Q89396965 | Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology |
| Q58615715 | Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer? |
| Q90279907 | Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer |
| Q90471688 | Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia |
| Q57788532 | Oncotype testing in patients undergoing intraoperative radiation for breast cancer |
| Q92238649 | Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ |
| Q38374747 | Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. |
| Q93167667 | SEOM clinical guidelines in early stage breast cancer (2018) |
| Q91647658 | The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy |
| Q57292624 | The effect of training interventions on physical performance, quality of life, and fatigue in patients receiving breast cancer treatment: a systematic review |
| Q92413756 | Unlocking the potential of population-based cancer registries |
| Q92830535 | Update on Precision Medicine in Breast Cancer |
Search more.